All In Biotech

Drug Trial Radar · NCT07670702

An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD

A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of TSND-201 for the Treatment of PTSD

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Dec 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Transcend TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.

Conditions

  • Post Traumatic Stress Disorder

Interventions

  • TSND-201Drug

    TSND-201 capsules, given orally; where a course of treatment includes dosing with TSND-201 once a week for four consecutive weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity ScoreTime frame: Up to 48 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners

    Little Rock, Arkansas

  • CalNeuro Research Group

    Los Angeles, California

  • Catalina Research Institute

    Montclair, California

  • Starlight Clinical Research

    Evergreen, Colorado

  • Clinical Neuroscience Solutions - Jacksonville

    Jacksonville, Florida

  • Segal Trials

    Lauderhill, Florida

  • Accel Clinical Research

    Maitland, Florida

  • CNS Healthcare

    Orlando, Florida

  • Vitalix Clinical

    Worcester, Massachusetts

  • Arch Clinical Trials

    Creve Coeur, Missouri

  • Bio Behavioral Health

    Toms River, New Jersey

  • Insight Clinical Trials

    Independence, Ohio

  • Flourish Research

    Plymouth Meeting, Pennsylvania

  • Austin Clinical Trial Partners

    Austin, Texas

  • Haracec Clinical Research

    El Paso, Texas

  • Cedar Clinical Research

    Draper, Utah

  • Inner Space Research

    Orem, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.